Access to innovative therapies
The aims of our research are to discover cures for myeloid malignancies and to uncover methods for preventing the development of acute myeloid leukemia. Our unique program has allowed us to rapidly achieve breakthroughs in both basic research science and clinical trials in which patients can benefit from the latest innovations.
Malignant Hematology Clinical Trials
Leukemia
Dr. O’Connell’s Research Studies
Myelodysplastic Syndrome:
- Tamibarotene Plus Azacitadine in Participants with Newly Diagnosed RARA – positive Higher – Risk Myelodysplastic Syndrome.
Myeloproliferative Neoplasm:
- A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Phlebotomy Dependent Polycythemia Vera (PD-PV).
- A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis
- Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination with Ruxolitinib in Participants with Anemia Due to Myeloproliferative Disorders
- Assessment of Cognitive Function in Patients with Myeloproliferative Neoplasms
- Molecular Contribution to Cytopenia’s in Patients with Cirrhosis.
Myelodysplastic Syndrome / Myeloproliferative Neoplasm
- A Phase 2, Double-blind, Randomized Study to Compare the Effect of Curcumin Versus Placebo on Inflammatory Cytokines, Symptoms and Disease Parameters in Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS), and Myeloproliferative Neoplasms (MPNs)
Idiopathic Erythrocytosis
- Prospective Study of Clinicopathologic Features and Mutation Frequency in Patients With Unexplained Erythrocytosis